Clinical Trials
Advanced Vision Research Institute
Since the Eye Care Center of Northern Colorado opened in 1969, our practitioners have been interested in the advancement of science and focused on offering the best patient care possible for all ocular conditions. We are now proud to announce the opening of Advanced Vision Research Institute. We are actively participating in clinical trials and providing access to medications and cutting-edge devices that would otherwise be unavailable to our patients.
Current Clinical Trials
Ascent
Protocol: RGX-314-3101
Sponsor: AbbVie
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
Indication: Neovascular (wet) age-related macular degeneration (wet AMD)
ClinicalTrials.gov Identifier: NCT05407636
ShORe
Protocol: OPT-302-1004
Sponsor: Opthea Limited
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
Indication: Neovascular (wet) age-related macular degeneration (wet AMD)
ClinicalTrials.gov Identifier: NCT04757610
HONU
Protocol: GE43220
Sponsor: Genentech, Inc.
A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
Indication: Age-Related Macular Degeneration
ClinicalTrials.gov Identifier: NCT05300724
ASPIRE
Protocol: UBX1325-04
Sponsor: Unity Biotechnology, Inc.
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema
Indication: Diabetic Macular Edema
ClinicalTrials.gov Identifier: NCT06011798
GO
Sponsor: Immunovant Sciences GmbH
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)
Indication: Active moderate to severe thyroid eye disease (TED)
ClinicalTrials.gov Identifier: NCT05517421
Closed Clinical Trials
Alexion / ALXN2040-GA-201
ClinicalTrials.gov Identifier: NCT05019521
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This Study is currently closed for enrollment with patients remaining in followup care.
Unity / UBX1325-02
ClinicalTrials.gov Identifier: NCT04857996
This is a Phase 2a Proof-of-Concept (POC) study. The study has enrolled approximately 62 patients that were randomized 1:1 into either the UBX1325 or sham study arms, in order to assess the primary objective(s). All patients are in a 24-week follow-up period.
This Study is currently closed for enrollment with patients remaining in followup care.
Olympia / OPP-102
ClinicalTrials.gov Identifier: NCT04957758
A Phase 2, Multicenter, Randomized, Controlled, Double Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (varenicline) Nasal Spray in Subjects with Neurotrophic Keratopathy (the Olympia Study)
This Study is currently closed for enrollment with patients remaining in followup care.
Unity / UBX1325-03
Clinicaltrials.gov ID: NCT05275205
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration (wet AMD)
This Study is currently closed for enrollment with patients remaining in followup care.